🏛️ Verified NIH Record • Updated 2025-12-12

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (NCT03013998)

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Beat AML, LLC

🩺 Plain-English Summary (8th-Grade Level)

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Patients with myeloid malignancies \[e.g. myelodysplastic syndrome (MDS) or other diseases\], will be allowed to enroll to Master protocol if there is an available sub-study.

Who can join: Review the eligibility criteria below.

Location: Mayo Clinic Arizona — Phoenix, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (19 Sites)

  • Mayo Clinic Arizona — Phoenix, Arizona
  • UCLA Ronald Reagan Medical Center — Los Angeles, California
  • University of California, San Francisco — San Francisco, California
  • University of Colorado — Denver, Colorado
  • University of Florida Health Shands Cancer Hospital — Gainesville, Florida
  • Mayo Clinic Florida — Jacksonville, Florida
  • Emory University — Atlanta, Georgia
  • University of Chicago — Chicago, Illinois
  • University of Kansas Clinical Research Center — Fairway, Kansas
  • University of Maryland Medical Center — Baltimore, Maryland
  • Mayo Clinic Minnesota — Rochester, Minnesota
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • UNC Hospitals, University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
  • University of Cincinnati Medical Center — Cincinnati, Ohio
  • Ohio State University — Columbus, Ohio
  • Oregon Health & Science University — Portland, Oregon
  • UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
  • University of Texas Southwestern — Dallas, Texas
  • Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah

📞 Contact the Study Coordinator

Phone: (301) 814-2788

Email: ashley.yocum@BloodCancerUnited.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Previously Untreated Relapsed Refractory Acute Myeloid Leukemia clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗